Issued 2026-08-13 at $2.39 · now $2.30 (2026-08-13, −3.8% since)
Based on its own history, a month from the 2026-08-13 close, NKTX has typically landed between $1.60 and $3.49 — a range of −33.2% to +46.1% from the issuance price $2.39.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,507 overlapping 1 month windows · 2020-07-10 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($2.39) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where NKTX has typically landed a month from the 2026-08-13 close of $2.39 — the range is history, not a prediction.
- now $2.3 (-3.8%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.27 (-4.9%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.91–$2.63
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.6–$3.49
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-06-05 | −59.6% | −59.6% | +1.4% |
| 2023-06-15 | −59.4% | −60.2% | +0.0% |
| 2023-06-13 | −57.7% | −58.2% | +5.1% |
| 3 best | |||
| 2023-12-06 | +272.3% | −0.4% | +272.3% |
| 2023-12-07 | +257.4% | −1.4% | +268.2% |
| 2023-12-08 | +255.7% | +0.0% | +273.6% |
1,507 overlapping windows · 2020-07-10 – 2026-08-13 · not cherry-picked
Pending catalysts
- April 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (source, as of 2026-08-14)
- October 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~7 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.